Encephalomyelitis - Pipeline Review, H1 2018

  • ID: 4464921
  • Drug Pipelines
  • 53 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biovista Inc
  • Grifols SA
  • Hemispherx Biopharma Inc
  • Johnson & Johnson
  • K-Pax Pharmaceuticals Inc
  • Philogen SpA
  • MORE
Encephalomyelitis - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Encephalomyelitis - Pipeline Review, H1 2018, provides an overview of the Encephalomyelitis (Central Nervous System) pipeline landscape.

Encephalomyelitis is an inflammation of the brain and spinal cord. Encephalomyelitis can be caused by a variety of conditions that lead to irritation of the brain and spinal cord. Among the common causes of encephalomyelitis are viruses which infect the nervous tissues. Signs and symptoms include neck stiffness, headache, and fever. Treatment includes antibiotics and corticosteroids.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Encephalomyelitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Encephalomyelitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalomyelitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, IND/CTA Filed and Preclinical stages are 1, 2, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Encephalomyelitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalomyelitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Encephalomyelitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Encephalomyelitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Encephalomyelitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Encephalomyelitis (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Encephalomyelitis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Encephalomyelitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biovista Inc
  • Grifols SA
  • Hemispherx Biopharma Inc
  • Johnson & Johnson
  • K-Pax Pharmaceuticals Inc
  • Philogen SpA
  • MORE
Introduction

The Publisher's Report Coverage

Encephalomyelitis - Overview

Encephalomyelitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Encephalomyelitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Encephalomyelitis - Companies Involved in Therapeutics Development

Aurigene Discovery Technologies Ltd

Biovista Inc

Grifols SA

Hemispherx Biopharma Inc

Johnson & Johnson

K-Pax Pharmaceuticals Inc

Philogen SpA

Encephalomyelitis - Drug Profiles

alpha-1 proteinase inhibitor (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FR-104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JM-4 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPAX-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nonathymulin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Preimplantation Factor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rintatolimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Chronic Fatigue Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate NF-E2 Related Factor 2 for Central Nervous System, Metabolic Disorders, Cardiovascular and Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetravil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

WEHI-345 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Encephalomyelitis - Dormant Projects

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Encephalomyelitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Encephalomyelitis - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Encephalomyelitis - Pipeline by Biovista Inc, H1 2018

Encephalomyelitis - Pipeline by Grifols SA, H1 2018

Encephalomyelitis - Pipeline by Hemispherx Biopharma Inc, H1 2018

Encephalomyelitis - Pipeline by Johnson & Johnson, H1 2018

Encephalomyelitis - Pipeline by K-Pax Pharmaceuticals Inc, H1 2018

Encephalomyelitis - Pipeline by Philogen SpA, H1 2018

Encephalomyelitis - Dormant Projects, H1 2018

Encephalomyelitis - Dormant Projects, H1 2018 (Contd..1), H1 2018

List of Figures

Number of Products under Development for Encephalomyelitis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aurigene Discovery Technologies Ltd
  • Biovista Inc
  • Grifols SA
  • Hemispherx Biopharma Inc
  • Johnson & Johnson
  • K-Pax Pharmaceuticals Inc
  • Philogen SpA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll